Posted by Michael Wonder on 18 Jan 2025
Arrowhead Pharmaceuticals announces acceptance of new drug application by US FDA of plozasiran for the treatment of familial chylomicronaemia syndrome
17 January 2025 - The new drug application is based on positive results from the Phase 3 PALISADE study.
Arrowhead Pharmaceuticals today announced that the US FDA has accepted the new drug application for investigational plozasiran for the treatment of familial chylomicronaemia syndrome, a severe and rare genetic disease.
